(Q24242946)

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Intracellular signal transduction pathway proteins as targets for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Sunitinib: from rational design to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Immunotherapy for advanced renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Emerging molecular classification in renal cell carcinoma: implications for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Metastatic renal cell cancer treatments: an indirect comparison meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

SUN vs BEVthornIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Targeted therapies for renal cell carcinoma: understanding their impact on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

The Phase III Trial in the Era of Targeted Therapy: Unraveling the “Go or No Go” Decision

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

21 January 2018

Targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

New targets, therapies, and toxicities: lessons to be learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

7 January 2021

Kidney cancer: now available in a new flavor

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

7 January 2021

Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

7 January 2021

Reply: SUN BEVIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

7 January 2021

First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

7 January 2021

Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

7 January 2021

Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

7 January 2021

Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

7 January 2021

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

7 January 2021

When does the presence of the target predict response to the targeted agent?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

7 January 2021

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

7 January 2021

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

7 January 2021

A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006017.PUB2

7 January 2021

10.1002/14651858.CD006017.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

18425931

1 reference

Consolidated OpenCitations Corpus – April 2017